CORREALE, MICHELE
 Distribuzione geografica
Continente #
EU - Europa 1.627
NA - Nord America 1.207
AS - Asia 305
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 3
AF - Africa 1
OC - Oceania 1
Totale 3.147
Nazione #
US - Stati Uniti d'America 1.205
IE - Irlanda 751
SE - Svezia 363
UA - Ucraina 270
CN - Cina 222
IT - Italia 96
AT - Austria 51
IN - India 49
FI - Finlandia 32
TR - Turchia 29
FR - Francia 21
DE - Germania 12
BE - Belgio 11
GB - Regno Unito 10
NL - Olanda 3
SG - Singapore 3
CA - Canada 2
ES - Italia 2
EU - Europa 2
JP - Giappone 2
PE - Perù 2
RU - Federazione Russa 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BR - Brasile 1
EG - Egitto 1
HR - Croazia 1
PL - Polonia 1
RO - Romania 1
Totale 3.147
Città #
Dublin 751
Nyköping 233
Chandler 187
Jacksonville 170
Ashburn 162
Dearborn 72
Princeton 61
Nanjing 60
Vienna 51
New York 47
Wilmington 45
Beijing 36
Seattle 29
Nanchang 22
Pune 22
Helsinki 21
San Mateo 17
Tianjin 15
Des Moines 14
Brussels 11
Shenyang 11
Foggia 9
Rome 9
Jiaxing 8
Renton 8
Washington 8
Changsha 7
Hangzhou 7
Kunming 7
Lund 7
Palermo 7
Stevenage 7
Woodbridge 7
Ann Arbor 6
Gesualdo 6
Guangzhou 6
Hebei 6
Jinan 6
Acerra 5
Bari 5
Ningbo 5
Changchun 4
Lanzhou 4
Messina 4
Norwalk 4
Philadelphia 4
San Severo 4
Apricena 3
Bisceglie 3
Borås 3
Los Angeles 3
Martina Franca 3
Redwood City 3
Shanghai 3
Stimigliano 3
Taglio Di Po 3
Zhengzhou 3
Augusta 2
Dallas 2
Hanover 2
Hefei 2
Hilden 2
Kolkata 2
Lima 2
New Delhi 2
Orange 2
Paris 2
Rockville 2
Taizhou 2
Valle 2
Agordo 1
Aprilia 1
Arzano 1
Benetutti 1
Bitonto 1
Boardman 1
Cairo 1
Chengdu 1
Cirié 1
Clearwater 1
Frankfurt am Main 1
Fuzhou 1
Glasgow 1
Haikou 1
Hubert 1
Hunedoara 1
Jackson 1
Kilcoy 1
Latina 1
Leawood 1
London 1
Milan 1
Novokuznetsk 1
Oristano 1
Peschici 1
Porto 1
Raleigh 1
Redmond 1
Reggio Emilia 1
Reno 1
Totale 2.283
Nome #
Alcohol-induced cardiac disease 95
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 84
EXPRESS: Don't stop at first glance; pulmonary artery angiosarcoma mimicking chronic thromboembolic pulmonary hypertension 84
Tissue Doppler Imaging predicts central sleep apnea in patients with chronic heart failure: data from the Daunia Registry 81
Typical Takotsubo syndrome and McConnell's phenomenon: What else lies beneath? 78
Cardiopulmonary exercise test predicts right heart catheterization 76
"PAFIYAMA" syndrome; further evidence on a novel clinical entity 75
Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability 75
Late onset of coronary vasospasm after administration of methyl-ergometrine for gynecologic bleeding. 72
Tako-Tsubo cardiomyopathy in a teen girl with pheochromocytoma. 71
Chronic thromboembolic pulmonary hypertension. 71
Recurrent Tako-Tsubo cardiomyopathy apparently induced by opposite triggers 69
Redefining biomarkers in heart failure 68
Delirium in heart failure 68
Inferior ST-Elevation Acute Myocardial Infarction or an Inferior-Lead Brugada-like Electrocardiogram Pattern Associated With the Use of Pregabalin and Quetiapine? 67
Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis 67
Liver disease and heart failure: Back and forth 67
Macitentan Use in a Neurofibromatosis Type 1 Patient With Pulmonary Hypertension and External Jugular Phlebectasia 66
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis 63
Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy 62
Tako-Tsubo cardiomyopathy recurrence in an elderly woman firstly diagnosed with acute myocardial infarction: How many cold cases to be reclassified? 60
COMPASS vs PEGASUS approach in a comparative budget impact analysis 59
HIV-associated pulmonary arterial hypertension: from bedside to the future 57
"ischemic" ST elevation in a woman with left ventricular hypertrophy 57
Fenofibrate and Dyslipidemia: Still a Place in Therapy? 57
SAT0325 Nailfold capillaroscopic changes in patients with idiopathic and systemic sclerosis-related pulmonary arterial ipertension 55
Liver disease and heart failure: an uptodate 53
Echocardiographic score for prediction of pulmonary hypertension at catheterization: The Daunia Heart Failure Registry 52
Biomarkers in cardiorenal syndrome 52
Influence of Heart Rate on Left and Right Ventricular Longitudinal Strain in Patients with Chronic Heart Failure 51
Tako-Tsubo cardiomyopathy or allergic acute coronary syndrome: that is the question. 50
Novel AKAP9 mutation and long QT syndrome in a patient with torsades des pointes 50
Advanced heart failure: non-pharmacological approach 49
Gastrointestinal bleeding and coagulation disorders in a patient with left-ventricular assist device 47
Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry 47
Cardiac contractility modulation in left ventricular systolic dysfunction: trick or treat? 46
Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry 45
Predictors of clinical improvement with sacubitril/valsartan in a real world population with chronic heart failure 45
Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: Where do we stand? 44
Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management 43
Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure 43
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 42
The thromboembolism in COVID-19: the unsolved problem 42
The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic 41
Disease-modifier Drugs in Patients with Advanced Heart Failure: How to Optimize Their Use? 39
Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure 39
Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation 38
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan 38
Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization 37
Chronic thromboembolic pulmonary hypertension mimicking coronary artery disease 37
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 37
Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure 36
New Targets in Heart Failure Drug Therapy 36
Infection, atherothrombosis and thromboembolism beyond the COVID-19 disease: what similar in physiopathology and researches 34
Delirium in heart failure 34
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 34
Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies 31
Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction 30
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 30
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 29
Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone 28
Effects of Sacubitril/Valsartan on the Renal Resistance Index 26
Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension 24
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients 24
LEAP Virtual Visit Assessment (VIVA): A structured protocol for virtual visits for patients with heart failure 20
Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study) 16
Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender 15
SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century? 11
Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan 10
Atrial paced rhythm and heart rate-dependent worsening of left atrial and ventricular function 6
Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest 5
Relationship between the strain measures of left atrial function and heart failure worsening 4
Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension 4
Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience 4
Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register 3
Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets 3
Imaging Modality to Guide Left Atrial Appendage Closure: Current Status and Future Perspectives 3
Alcohol consumption and subclinical and clinical coronary heart disease: New insight into potential causal mechanisms 3
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples 3
Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry 3
Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy 3
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 3
The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction 3
Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study 3
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis 3
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner? 3
Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach 3
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 3
Switch to Gliflozins and Biventricular Function Improvement in Patients with Chronic Heart Failure and Diabetes Mellitus 3
Totale 3.447
Categoria #
all - tutte 19.349
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.349


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201972 0 0 0 0 0 0 0 6 12 7 12 35
2019/2020382 68 28 6 2 40 51 67 9 50 14 44 3
2020/2021371 50 7 42 12 43 3 51 54 52 56 1 0
2021/2022412 17 2 11 3 70 14 11 38 49 86 6 105
2022/20231.450 117 69 83 38 31 104 2 92 811 10 44 49
2023/2024448 57 18 39 20 85 124 13 92 0 0 0 0
Totale 3.447